Discussant review - CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy: treatment effect in hereditary vs. wild-type disease

17 May 2025 (08:00 - 12:45)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Professor Rudolf De Boer

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

20 More presentations in this session

Presentation thumbnail

FINEARTSHF: Blinded drug withdrawal

Doctor M. Vaduganathan (Boston, US)

Presentation thumbnail

Discussant review - FINEARTS-HF

Doctor M. Costanzo (Naperville, US)

Presentation thumbnail

Panel discussion - FINEARTS-HF

Presentation thumbnail

FAIR-HF2 DZHK05: Efficacy of ferric carboxymaltose in heart failure and iron deficiency stratified by transferrin saturation

Professor S. Anker (Berlin, DE)

Presentation thumbnail

Discussant review - FAIR-HF2 DZHK05

Doctor V. Chopra (New Delhi, IN)

Access the full session

Session thumbnail

Hottest trials and trial updates (1)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025

You may be interested in

Congress Presentation

CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy: treatment effect in hereditary vs. wild-type disease

Congress Presentation

Design and rationale for MAGNITUDE, a phase 3, randomised, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy

Congress Presentation

Amyloid-specific medication in transthyretin amyloid cardiomyopathy: a systemic review and meta-analysis.

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources